GlassScriptPhysician profile
Mary Ameh
NPI 1063881274
$3,724.04
in general payments reported to CMS, 2019-2025
24 companies · $864 in 2025
The $864 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $761 · 2022: $728 · 2023: $1,022 · 2024: $349 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,234.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,149.18 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $425.85 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $407.82 | 2022-2025 | Austedo Xr, Austedo, Uzedy |
| Janssen Pharmaceuticals, INC | $388.97 | 2023-2025 | Invega Sustenna, Spravato |
| Alkermes, INC. | $256.31 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
| Supernus Pharmaceuticals, INC. | $197.69 | 2021-2025 | Qelbree, Qelbree |
| Lilly USA, LLC | $140.39 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.05 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $113.81 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $104.87 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $88.53 | 2023-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $60.00 | 2022-2023 | Quviviq |
| Lundbeck LLC | $54.16 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $39.48 | 2025 | Cobenfy |
| Novo Nordisk INC | $27.69 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $24.28 | 2023 | Hillrom - Life 2000 Ventilation System |
| Biohaven Pharmaceuticals, INC. | $20.06 | 2021 | |
| Medtronic, INC. | $18.12 | 2023 | Intellis Adaptivestim |
| Impel Pharmaceuticals INC. | $16.92 | 2022 | |
| Phadia US INC. | $15.30 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.96 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.21 | 2023 | Linzess |
| Paratek Pharmaceuticals, INC. | $12.74 | 2023 | Nuzyra |
| Currax Pharmaceuticals LLC | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Ameh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.